Loading clinical trials...
Loading clinical trials...
Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas
Conditions
Interventions
Treatment Period 1
Treatment Period 2
+2 more
Locations
2
United States
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
Johns Hopkins University/Johns Hopkins Hospital
Baltimore, Maryland, United States
Start Date
March 3, 2023
Primary Completion Date
February 1, 2026
Completion Date
May 1, 2027
Last Updated
November 29, 2024
NCT05969860
NCT02800486
NCT05789394
NCT06934889
NCT05839379
NCT00083512
Lead Sponsor
SignPath Pharma, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions